Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma

Published:2004-06 Issue:5 Volume:15 Page:427-437
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Reidy Diane L.,Schwartz Jonathan D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference37 articles.

1. Liver Cancer;Bosch,1997

2. Cancer statistics 1999;Landis;Cancer J Clin,1999

3. Mortality by cause for eight regions of the world: global burden of disease study;Murray;Lancet,1997

4. Rising incidence of hepatocellular carcinoma in the United States;El-Serag;N Engl J Med,1999

5. Long interval between HCV infection and development of hepatocellular carcinoma;Castells;Liver,1995

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma;Asia-Pacific Journal of Clinical Oncology;2024-08-25

2. Transarterielle Chemoembolisation des hepatozellulären Karzinoms;Der Radiologe;2022-02-16

3. 131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment;Journal of Gastrointestinal Oncology;2021-04

4. Published trials of TACE for HCC are often not registered and subject to outcome reporting bias;JHEP Reports;2021-02

5. Development of a Methodology for the Analysis and Evaluation of Alternative Actions in Disruption Management in Production;Collaborative Networks and Digital Transformation;2019